13G Filing: Foresite Capital Fund III, L.P. and Tocagen Inc (TOCA)

Page 5 of 9 – SEC Filing

ITEM 1(A). NAME OF ISSUER
Tocagen Inc. (the “Issuer”)
ITEM 1(B). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
3030 Bunker Hill Street, Suite 230
San Diego, California 92109
ITEM 2(A). NAME OF PERSONS FILING
This Schedule is filed by Foresite Capital Fund III, L.P., a Delaware limited partnership, Foresite Capital Management III, LLC, a Delaware limited liability company, and James Tananbaum.  The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”
ITEM 2(B). ADDRESS OF PRINCIPAL OFFICE
The address for each of the Reporting Persons is:
c/o Foresite Capital Management
600 Montgomery Street, Suite 4500
San Francisco, CA 94111
ITEM 2(C). CITIZENSHIP
See Row 4 of cover page for each Reporting Person.
ITEM 2(D). TITLE OF CLASS OF SECURITIES
Common Stock
ITEM 2(D) CUSIP NUMBER
888846102
ITEM 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:
  Not applicable.

Follow Forte Biosciences Inc. (NASDAQ:FBRX)